KR20210136052A - Hiv 요법에 유용한 화합물 - Google Patents

Hiv 요법에 유용한 화합물 Download PDF

Info

Publication number
KR20210136052A
KR20210136052A KR1020217031465A KR20217031465A KR20210136052A KR 20210136052 A KR20210136052 A KR 20210136052A KR 1020217031465 A KR1020217031465 A KR 1020217031465A KR 20217031465 A KR20217031465 A KR 20217031465A KR 20210136052 A KR20210136052 A KR 20210136052A
Authority
KR
South Korea
Prior art keywords
mmol
fluoro
purin
alkyl
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
KR1020217031465A
Other languages
English (en)
Korean (ko)
Inventor
마르타 알리시아 데 라 로사
존 에프. 밀러
데이비드 테멜코프
에밀 요한 벨투이센
비. 나라심훌루 나이두
비센테 사마노
Original Assignee
글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드
비이브 헬쓰케어 컴퍼니
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69845479&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=KR20210136052(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드, 비이브 헬쓰케어 컴퍼니 filed Critical 글락소스미스클라인 인털렉츄얼 프로퍼티 (넘버 2) 리미티드
Publication of KR20210136052A publication Critical patent/KR20210136052A/ko
Withdrawn legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
    • C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
    • C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
    • C07H19/16—Purine radicals
    • C07H19/173—Purine radicals with 2-deoxyribosyl as the saccharide radical

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • AIDS & HIV (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
KR1020217031465A 2019-03-06 2020-03-04 Hiv 요법에 유용한 화합물 Withdrawn KR20210136052A (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962814316P 2019-03-06 2019-03-06
US62/814,316 2019-03-06
PCT/IB2020/051878 WO2020178767A1 (en) 2019-03-06 2020-03-04 Compounds useful in hiv therapy

Publications (1)

Publication Number Publication Date
KR20210136052A true KR20210136052A (ko) 2021-11-16

Family

ID=69845479

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217031465A Withdrawn KR20210136052A (ko) 2019-03-06 2020-03-04 Hiv 요법에 유용한 화합물

Country Status (22)

Country Link
US (4) US12240853B2 (cg-RX-API-DMAC7.html)
EP (1) EP3934760A1 (cg-RX-API-DMAC7.html)
JP (1) JP2022525013A (cg-RX-API-DMAC7.html)
KR (1) KR20210136052A (cg-RX-API-DMAC7.html)
CN (1) CN113811360A (cg-RX-API-DMAC7.html)
AR (1) AR118240A1 (cg-RX-API-DMAC7.html)
AU (1) AU2020231934B2 (cg-RX-API-DMAC7.html)
BR (1) BR112021017604A2 (cg-RX-API-DMAC7.html)
CA (1) CA3132112A1 (cg-RX-API-DMAC7.html)
CL (1) CL2021002309A1 (cg-RX-API-DMAC7.html)
CO (1) CO2021012579A2 (cg-RX-API-DMAC7.html)
CR (1) CR20210460A (cg-RX-API-DMAC7.html)
EA (1) EA202192433A1 (cg-RX-API-DMAC7.html)
IL (1) IL285894A (cg-RX-API-DMAC7.html)
MA (1) MA55200A (cg-RX-API-DMAC7.html)
MX (1) MX2021010700A (cg-RX-API-DMAC7.html)
PE (1) PE20212089A1 (cg-RX-API-DMAC7.html)
PH (1) PH12021500034A1 (cg-RX-API-DMAC7.html)
SG (1) SG11202109253SA (cg-RX-API-DMAC7.html)
TW (1) TW202102233A (cg-RX-API-DMAC7.html)
WO (1) WO2020178767A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202106096B (cg-RX-API-DMAC7.html)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL289925B2 (en) 2019-07-27 2026-03-01 Brii Biosciences Inc A derivative of adenosine and a pharmaceutical preparation containing it
MX2022002897A (es) 2019-09-11 2022-05-16 Scripps Research Inst Profarmacos antivirales y formulaciones de los mismos.
IL293566A (en) * 2019-12-09 2022-08-01 Viiv Healthcare Co Pharmaceutical preparations containing Cabotgravir
KR102987126B1 (ko) * 2020-03-20 2026-07-07 길리애드 사이언시즈, 인코포레이티드 4'-c-치환된-2-할로-2'-데옥시아데노신 뉴클레오시드의 프로드러그 및 이의 제조 및 사용 방법
CN116370479B (zh) * 2020-12-30 2024-02-13 南方科技大学 化合物atv014在制备用于治疗新冠病毒感染的产品中的用途
AU2022211056A1 (en) * 2021-01-25 2023-07-20 Brii Biosciences, Inc. Combination therapy for hiv with adenosine derivative and capsid inhibitors
KR20230132476A (ko) * 2021-01-25 2023-09-15 브리 바이오사이언시스, 인크. 아데노신 유도체 및 이를 포함하는 약제학적 조성물
WO2022182604A1 (en) * 2021-02-23 2022-09-01 Viiv Healthcare Company Compounds useful in hiv treatment
EP4658663A2 (en) * 2023-01-30 2025-12-10 Merck Sharp & Dohme LLC Prodrugs of 4'-substituted nucleoside reverse transcriptase inhibitors
US20250099464A1 (en) 2023-09-27 2025-03-27 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB427857A (en) 1934-08-02 1935-05-01 Newsum Sons & Company Ltd H A new or improved system of construction for skeleton structures, particularly vehicle body frames and door frames
US4107288A (en) 1974-09-18 1978-08-15 Pharmaceutical Society Of Victoria Injectable compositions, nanoparticles useful therein, and process of manufacturing same
US5145684A (en) 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
DE60005502T2 (de) 1999-05-12 2004-06-24 Yamasa Corp., Choshi 4'-c-ethynyl-purin-nukleoside
WO2002074769A1 (en) 2001-03-19 2002-09-26 Ono Pharmaceutical Co., Ltd. Drugs containing triazaspiro[5.5]undecane derivatives as the active ingredient
US7037718B2 (en) 2001-10-26 2006-05-02 Cornell Research Foundation, Inc. Mutant purine nucleoside phosphorylase proteins and cellular delivery thereof
CA2502109C (en) * 2004-03-24 2010-02-23 Yamasa Corporation 4'-c-substituted-2-haloadenosine derivative
CN100532388C (zh) 2007-07-16 2009-08-26 郑州大学 2’-氟-4’-取代-核苷类似物、其制备方法及应用
US20090318380A1 (en) 2007-11-20 2009-12-24 Pharmasset, Inc. 2',4'-substituted nucleosides as antiviral agents
US8927513B2 (en) 2009-07-07 2015-01-06 Alnylam Pharmaceuticals, Inc. 5′ phosphate mimics
US9198972B2 (en) 2010-01-28 2015-12-01 Alnylam Pharmaceuticals, Inc. Monomers and oligonucleotides comprising cycloaddition adduct(s)
US9725479B2 (en) 2010-04-22 2017-08-08 Ionis Pharmaceuticals, Inc. 5′-end derivatives
AU2011305652B2 (en) 2010-09-22 2016-10-20 Janssen Biopharma, Inc. Azido nucleosides and nucleotide analogs
UY34372A (es) 2011-10-06 2013-05-31 Dow Agrosciences Llc Moléculas de ácido nucleico que se dirigen a rpa70 y confieren resistencia a plagas de coleópteros.
KR102072041B1 (ko) 2011-12-22 2020-01-31 앨리오스 바이오파마 인크. 치환된 뉴클레오사이드, 뉴클레오타이드 및 그의 유사체
SI2827875T1 (sl) 2012-03-21 2019-04-30 Alios Biopharma, Inc. Substituirani nukleozidi, nukleotidi in njihovi analogi
US9441007B2 (en) 2012-03-21 2016-09-13 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
ES2952714T3 (es) 2013-06-26 2023-11-03 Janssen Pharmaceuticals Inc Nucleósidos sustituidos, nucleótidos y análogos de los mismos
CN105829333A (zh) 2013-10-11 2016-08-03 艾丽奥斯生物制药有限公司 取代的核苷、核苷酸及其类似物
WO2015143712A1 (en) 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
US9603864B2 (en) 2014-06-24 2017-03-28 Alios Biopharma, Inc. Substituted nucleosides, nucleotides and analogs thereof
SG11201610597QA (en) 2014-06-24 2017-01-27 Alios Biopharma Inc Substituted nucleosides, nucleotides and analogs thereof
WO2016057866A1 (en) 2014-10-09 2016-04-14 Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
CN107074899A (zh) * 2014-10-31 2017-08-18 桑多斯股份公司 改进的氟化工艺
MA41213A (fr) 2014-12-19 2017-10-24 Alios Biopharma Inc Nucléosides substitués, nucléotides et analogues de ceux-ci
JP6768796B2 (ja) * 2015-09-23 2020-10-14 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. 4’−置換ヌクレオシド逆転写酵素阻害剤及びその調製
JOP20170038B1 (ar) * 2016-02-12 2021-08-17 Merck Sharp & Dohme مركبات للاستخدام لعلاج عدوى بفيروس hiv والوقاية منه
JP7160466B2 (ja) 2016-06-23 2022-10-25 ヴィーブ ヘルスケア カンパニー 治療薬の送達のための組成物及び方法
WO2018085307A1 (en) 2016-11-03 2018-05-11 Wu Laurence I Prodrugs of clofarabine
US20190185508A1 (en) 2017-12-15 2019-06-20 Merck Sharp & Dohme Corp. Deuterated nucleoside reverse transcriptase inhibitors
WO2019171285A1 (en) * 2018-03-07 2019-09-12 Glaxosmithkline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
CA3096400A1 (en) 2018-04-09 2019-10-17 Eisai R&D Management Co., Ltd. Certain pladienolide compounds and methods of use
MA53280A (fr) 2018-08-09 2021-11-17 Glaxosmithkline Ip No 2 Ltd Composés utiles dans la thérapie du vih
US20210323993A1 (en) 2018-08-30 2021-10-21 Glaxosmithkline Intellectual Property (No. 2) Limited Compounds Useful in HIV Therapy
US12018435B2 (en) 2019-03-06 2024-06-25 Chemstone, Inc. Liquid dispersions for acyl halides

Also Published As

Publication number Publication date
PE20212089A1 (es) 2021-11-04
US20260035371A1 (en) 2026-02-05
TW202102233A (zh) 2021-01-16
CO2021012579A2 (es) 2021-10-20
BR112021017604A2 (pt) 2021-11-16
EP3934760A1 (en) 2022-01-12
ZA202106096B (en) 2023-03-29
US12240853B2 (en) 2025-03-04
EA202192433A1 (ru) 2021-12-28
US20230174534A1 (en) 2023-06-08
US20220411425A1 (en) 2022-12-29
CR20210460A (es) 2022-02-03
WO2020178767A1 (en) 2020-09-10
AU2020231934B2 (en) 2023-04-20
MX2021010700A (es) 2021-10-01
CA3132112A1 (en) 2020-09-10
PH12021500034A1 (en) 2022-06-06
SG11202109253SA (en) 2021-09-29
AU2020231934A8 (en) 2022-03-24
AU2020231934A1 (en) 2021-09-23
IL285894A (en) 2021-10-31
AR118240A1 (es) 2021-09-22
US20240182473A1 (en) 2024-06-06
MA55200A (fr) 2022-01-12
JP2022525013A (ja) 2022-05-11
CL2021002309A1 (es) 2022-09-20
CN113811360A (zh) 2021-12-17

Similar Documents

Publication Publication Date Title
US20260035371A1 (en) Compounds useful in hiv therapy
US20210323993A1 (en) Compounds Useful in HIV Therapy
WO2021038509A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
AU2019317810A1 (en) Compounds useful in HIV therapy
EP3762396A1 (en) Compounds useful in hiv therapy
EP2791102B1 (en) Propenoate derivatives of betulin
US20230151049A1 (en) Compounds Useful in HIV Therapy
CA3082867A1 (en) Crystalline 2-amino-2-(hydroxymethyl)propane-1,3-diol salt of 4-(4-(1-isopropyl-7-oxo-1,4,6,7-tetrahydrospiro[indazole-5,4'-piperidine]-1'-carbonyl)-6-methoxypyridin-2-yl)benzoic acid
KR20180054826A (ko) Hiv 성숙 억제 활성을 갖는 화합물
EP4010349A1 (en) 4'-ethynyl-2'-deoxyadenosine derivatives and their use in hiv therapy
KR20180028535A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체
KR20180028534A (ko) Hiv 감염을 예방하거나 치료하기 위한 베투인 유도체

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210930

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
PC1202 Submission of document of withdrawal before decision of registration

Comment text: [Withdrawal of Procedure relating to Patent, etc.] Withdrawal (Abandonment)

Patent event code: PC12021R01D

Patent event date: 20230822

WITB Written withdrawal of application